Julie Kim (left)
President, Plasma-Derived Therapies Business Unit
Marcello Agosti (right)
Global Business Development Officer
How is diversity, equity and inclusion evolving at Takeda?
Julie: It’s a priority to make a positive impact in this area — both inside and outside of our organization. Our ambition is to drive positive change by promoting and improving diversity, equity and inclusion with a focus on proactively eliminating bias. This is inclusive of underrepresented groups at the country level and globally. What we’re aiming to do at the global level is develop principles, frameworks and programs that will truly add value, and establish metrics to hold ourselves accountable. We’re committed to facilitating both companywide efforts and grassroots initiatives that address regional nuances and leverage local advocates as sponsors.
How does the recent focus on addressing social justice and equality issues affect Takeda’s approach?
Marcello: It’s helped to accelerate our progress as we recognize that we have a lot of room for growth in many areas and locations. We’re operating at multiple levels — globally we’re establishing a Diversity, Equity & Inclusion team to support companywide initiatives. Regionally, locally and at the functional level, we will continue with the efforts in place, working closely with our TRGs.
Julie: We will not tolerate any type of discrimination at Takeda. We’ll continue to foster an environment at our company where people of diverse backgrounds, cultures and perspectives work together to inspire and enable health innovation for our patients. In addition, we need to make small but important changes in behavior to be inclusive, not just with our colleagues but also patients, partners and other stakeholders. As a values-based organization, we need to offer help and support where we see an opportunity to make a positive impact.